Tempus AI Bets on MRD Testing Growth With Personalis Acquisition

• MarketBeat Week successful Review – 02/23 - 02/27

Tempus AI (NASDAQ:TEM) executives said the company's planned acquisition of Personalis is intended to fortify its presumption successful minimal residual disease, oregon MRD, testing, portion expanding its biopharma information and profiling capabilities.

On a telephone with analysts, Tempus said it agreed to get each outstanding shares of Personalis not already owned by Tempus astatine $16.25 per share. The institution said the terms represents a 6% premium to Personalis' Friday closing terms and a 28% premium to its unaffected 30-day volume-weighted mean price.

→ MarketBeat Week successful Review – 07/13- 07/17

• After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound

The information is structured arsenic 100% stock, though Tempus has the enactment to wage up to 50% successful cash. Personalis shareholders would person a floating speech ratio of Tempus communal banal for each Personalis stock held astatine closing, taxable to a maximum speech ratio of 0.3356. Tempus said immoderate currency information could beryllium financed with currency connected manus and further borrowing procured betwixt signing and closing. The companies expect the transaction to adjacent successful precocious 2026 oregon aboriginal 2027.

Tempus Points to MRD Growth and Reimbursement Momentum

Tempus said Personalis' NeXT Personal offering has seen beardown adoption, with quarter-over-quarter maturation of 38%. The institution said volumes could go "even much worldly and higher" arsenic further income representatives are equipped to merchantability the offering and arsenic much indications unafraid reimbursement.

→ Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop

• Tempus AI Sold Off After a Beat—But the Rebound Case Is Building

In effect to a question from Kallum Titchmarsh of Morgan Stanley, an enforcement identified arsenic Eric said Tempus is "quickly gaining marketplace adoption," citing some wide maturation successful the MRD marketplace and the show of Personalis' assay. He said Tempus expects to embed much of its exertion into the MRD offering implicit time, including infirmary connectivity, AI-enabled ordering tools and AI-derived insights.